retatrutide phase 3 triumph just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight ⭐️topline results from TRIUMPH-1, a

It's also important for patients to have realistic expectations about the results and to understand that these medications are most effective when used in conjunction with lifestyle changes, including diet and exercise

While still highly effective, it falls short of the results seen with tirzepatide

Patients commonly contact us from: Telehealth consultations make it possible for eligible patients throughout Florida to discuss medical weight loss treatment options from the comfort of home

This article explores the biology of GLP-1, reviews current and emerging therapies, and examines their implications for the future of drug discovery and development

In the United States, tirzepatide is sold under two brand names